New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment

Journal of Experimental & Clinical Cancer Research : CR
Daniela CriscuoloAngela Celetti

Abstract

Novel therapeutic strategies are urgently needed for the treatment of metastatic Urothelial Bladder Cancer. DNA damaging repair (DDR) targeting has been introduced in cinical trials for bladder cancer patients that carry alterations in homologous DNA repair genes, letting to envisage susceptibility to the Poly (adenosine diphosphate [ADP]) ribose polymerase (PARP) inhibitors. PARP inhibition, by amplifying the DNA damage, augments the mutational burden and promotes the immune priming of the tumor by increasing the neoantigen exposure and determining upregulation of programmed death ligand 1 (PD-L1) expression. Thus, the combination of PARP-inhibition and the PD/PD-L1 targeting may represent a compelling strategy to treat bladder cancer and has been introduced in recent clinical trials. The targeting of DDR has been also used in combination with epigenetic drugs able to modulate the expression of genes involved in DDR, and also able to act as immunomodulator agents suggesting their use in combination with immune-checkpoint inhibitors. In conclusion, it may be envisaged the combination of three classes of drugs to treat bladder cancer, by targeting the DDR process in a tumor context of DDR defect, together with epigenetic agents ...Continue Reading

References

Oct 29, 2004·Nature Reviews. Cancer·Nicholas TurnerAlan Ashworth
Mar 3, 2006·Cancer Research·Carlo StresemannFrank Lyko
Feb 27, 2007·Cell·Tony Kouzarides
Sep 19, 2007·Molecular and Cellular Biology·A Francesca SetiadiWilfred A Jefferies
Mar 14, 2008·The New England Journal of Medicine·Manel Esteller
Oct 23, 2010·Molecular Cell·Alberto Ciccia, Stephen J Elledge
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Jan 13, 2012·Current Opinion in Immunology·Suzanne L TopalianDrew M Pardoll
Jan 20, 2012·Nature·Christopher J Lord, Alan Ashworth
Apr 4, 2012·Biochemical Pharmacology·Mike De VosFrançoise Dantzer
Oct 9, 2012·Seminars in Oncology·Joaquim Bellmunt, Daniel P Petrylak
Nov 3, 2012·Cancer Research·Junko MuraiYves Pommier
Sep 26, 2013·BMC Cancer·Stefania StaibanoAngela Celetti
Nov 16, 2013·Science·Sebastian M B Nijman, Stephen H Friend
Jan 5, 2014·Pharmacology & Therapeutics·Luca SigalottiMichele Maio
Jan 16, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Tamer E FandySteven D Gore
Jan 31, 2014·Nature·UNKNOWN Cancer Genome Atlas Research Network
Jul 2, 2014·Nature Reviews. Genetics·Thomas HelledaySerena Nik-Zainal
Jul 31, 2014·Nucleic Acids Research·Manuel Luis OrtaThomas Helleday
Sep 16, 2014·International Journal of Cancer. Journal International Du Cancer·Jacques FerlayFreddie Bray
Oct 11, 2014·International Journal of Cancer. Journal International Du Cancer·Francesco MorraAngela Celetti
Jan 31, 2015·Cancer Research·Raphael CeccaldiPanagiotis A Konstantinopoulos
Apr 4, 2015·Science·Ton N Schumacher, Robert D Schreiber
Jul 19, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey KimRichard Pazdur
Sep 12, 2015·Science·Eliezer M Van AllenLevi A Garraway
Sep 17, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michele MaioLuca Sigalotti
Nov 23, 2015·Molecular Cell·Mark J O'Connor
Nov 26, 2015·Nature Reviews. Immunology·Glen N Barber
Feb 13, 2016·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T Helleday
Mar 19, 2016·Cancer Research·Katherine B ChiappinelliStephen B Baylin

❮ Previous
Next ❯

Citations

Sep 16, 2019·Journal of Hematology & Oncology·Anping LiKongming Wu
Sep 16, 2020·Journal of Experimental & Clinical Cancer Research : CR·Mingming JinGang Huang
Mar 3, 2020·Frontiers in Oncology·Rohan GarjeYousef Zakharia
Aug 8, 2020·Expert Review of Anticancer Therapy·Veronica MollicaFrancesco Massari
May 29, 2020·Journal of Experimental & Clinical Cancer Research : CR·Liang ChenTeng Hou
Sep 16, 2020·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Anca Chelariu-RaicuRobert L Coleman
Feb 16, 2021·Frontiers in Oncology·Mei PengXiaoping Yang
Dec 15, 2020·Current Breast Cancer Reports·Jamaal L James, Justin M Balko
Mar 26, 2021·Clinical Oncology : a Journal of the Royal College of Radiologists·T LodhiA Choudhury
Apr 2, 2021·Circulation Research·Daan C H van DorstNinian N Lang
Apr 4, 2021·International Journal of Molecular Sciences·Florus C de JongDan Theodorescu
Apr 8, 2021·Nature Reviews. Urology·Weranja RanasingheBrian F Chapin
Apr 28, 2021·Expert Opinion on Pharmacotherapy·Ariana L SantopietroJoaquim Bellmunt
Feb 14, 2021·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Laura N PuentesRobert H Mach
Jul 27, 2021·Frontiers in Molecular Biosciences·Alejandra FernandezAmila Suraweera
Aug 23, 2021·Biochimica Et Biophysica Acta. Reviews on Cancer·Manendra Singh TomarAshutosh Shrivastava
Jul 6, 2020·Bulletin du cancer·Constance Thibault, Marine Gross-Goupil

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
histone acetylation

Clinical Trials Mentioned

NCT03375307
NCT03448718
NCT03397394
NCT02736266
NCT02951767
NCT02108652
NCT02546661
NCT03534492
NCT03459846
NCT02619253

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

International Journal of Oral Science
Gong-She GuoSimon N Powell
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Elizabeth H StoverElizabeth M Swisher
© 2022 Meta ULC. All rights reserved